Mainolfi Nello's Form 4 filing
Kymera Therapeutics, Inc. (KYMR) · filed Aug 2, 2021
- Accession no.
- 0001209191-21-049110
- Filed
- Aug 2, 2021
- Trade date
- Jul 29-Aug 2, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 8 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.83M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mainolfi NelloCIK 0001821189 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 29, 2021 | Common Stock | MOption exerciseAcquired | +680 | $2.08 | +$1,414.4 | 452,879 | Direct | |
| Jul 29, 2021 | Common Stock | SSaleDisposed | −680 | $60.00 | −$40,800 | 452,199 | Direct | |
| Jul 30, 2021 | Common Stock | MOption exerciseAcquired | +6,279 | $2.08 | +$13,060.32 | 458,478 | Direct | |
| Jul 30, 2021 | Common Stock | SSaleDisposed | −6,279 | $60.07F2 | −$377,179.53 | 452,199 | Direct | |
| Aug 2, 2021 | Common Stock | MOption exerciseAcquired | +23,456 | $2.08 | +$48,788.48 | 475,655 | Direct | |
| Aug 2, 2021 | Common Stock | SSaleDisposed | −21,632 | $60.21F3 | −$1,302,462.72 | 454,023 | Direct | |
| Aug 2, 2021 | Common Stock | SSaleDisposed | −1,524 | $61.28F4 | −$93,390.72 | 452,499 | Direct | |
| Aug 2, 2021 | Common Stock | SSaleDisposed | −300 | $62.21F5 | −$18,663 | 452,199 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 29, 2021 | Common Stock | MOption exerciseDisposed | −680 | $0.00 | $0 | 113,166 | Direct | |
| Jul 30, 2021 | Common Stock | MOption exerciseDisposed | −6,279 | $0.00 | $0 | 106,887 | Direct | |
| Aug 2, 2021 | Common Stock | MOption exerciseDisposed | −23,456 | $0.00 | $0 | 83,431 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.00 to $61.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.205 to $62.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.